Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1982 Mar;79(5):1658–1662. doi: 10.1073/pnas.79.5.1658

Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists.

G Tolis, D Ackman, A Stellos, A Mehta, F Labrie, A T Fazekas, A M Comaru-Schally, A V Schally
PMCID: PMC346035  PMID: 6461861

Abstract

Ten patients with prostatic carcinoma--six with stage C and four with stage D disease--were treated for 6 weeks to 12 months with agonistic analogues of luteinizing hormone-releasing hormone (LH-RH). [D-Trp6]LH-RH was given subcutaneously once daily at a dose of 100 microgram and [D-Ser(But)6]des-GlyNH2(10)-LH-RH ethylamide (HOE 766) was given subcutaneously (50 microgram once daily) or intranasally (500 microgram twice daily). In all patients, mean plasma testosterone levels showed a 75% suppression by the third week of treatment and remained low thereafter. This was followed by a decrease or normalization of plasma acid phosphatase levels by the second month of treatment and a 47% decrease in serum alkaline phosphatase by the 10th week of treatment in all but one patient. In patients with stage C disease presenting with prostatism or urinary outflow obstruction, there was a noticeable clinical improvement. In two such patients, a decrease in the size of the prostate was confirmed by ultrasonography. In patients with stage D disease manifested by diffuse bone metastases, there was relief of bone pain, and in one patient treated for greater than 12 months the improvement was documented by radioisotope bone imaging. It is concluded that superactive agonistic LH-RH analogues hold promise as therapeutic agents in patients with androgen-sensitive prostatic adenocarcinoma. Furthermore, the analogous of LH-RH may be used to assess the responsiveness of patients to surgical castration. Long-term administration of LH-RH analogues could become an alternative to surgical castration and estrogen therapy for the treatment of hormone-dependent prostatic carcinoma.

Full text

PDF
1658

Images in this article

1659Image
on p.1659
1661Image
on p.1661
1661Image
on p.1661

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Auclair C., Kelly P. A., Labrie F., Coy D. H., Schally A. V. Inhibition of testicular luteinizing hormone receptor level by treatment with a potent luteinizing hormone-releasing hormone agonist of human chorionic gonadotropin. Biochem Biophys Res Commun. 1977 Jun 6;76(3):855–862. doi: 10.1016/0006-291x(77)91579-0. [DOI] [PubMed] [Google Scholar]
  2. Bergquist C., Nillius S. J., Bergh T., Skarin G., Wide L. Inhibitory effects on gonadotrophin secretion and gonadal function in men during chronic treatment with a potent stimulatory luteinizing hormone-releasing hormone analogue. Acta Endocrinol (Copenh) 1979 Aug;91(4):601–608. doi: 10.1530/acta.0.0910601. [DOI] [PubMed] [Google Scholar]
  3. Bélanger A., Caron S., Picard V. Simultaneous radioimmunoassay of progestins, androgens and estrogens in rat testis. J Steroid Biochem. 1980 Feb;13(2):185–190. doi: 10.1016/0022-4731(80)90190-9. [DOI] [PubMed] [Google Scholar]
  4. Coy D. H., Vilchez-Martinez J. A., Coy E. J., Schally A. V. Analogs of luteinizing hormone-releasing hormone with increased biological activity produced by D-amino acid substitutions in position 6. J Med Chem. 1976 Mar;19(3):423–425. doi: 10.1021/jm00225a018. [DOI] [PubMed] [Google Scholar]
  5. Crowley W. F., Jr, Comite F., Vale W., Rivier J., Loriaux D. L., Cutler G. B., Jr Therapeutic use of pituitary desensitization with a long-acting lhrh agonist: a potential new treatment for idiopathic precocious puberty. J Clin Endocrinol Metab. 1981 Feb;52(2):370–372. doi: 10.1210/jcem-52-2-370. [DOI] [PubMed] [Google Scholar]
  6. DeSombre E. R., Johnson E. S., White W. F. Regression of rat mammary tumors effected by a gonadoliberin analog. Cancer Res. 1976 Oct;36(10):3830–3833. [PubMed] [Google Scholar]
  7. Dericks-Tan J. S., Hammer E., Taubert H. D. The effect of D-ser (TBU)6-LH-RH-EA10 upon gonadotropin release in normally cyclic women. J Clin Endocrinol Metab. 1977 Sep;45(3):597–600. doi: 10.1210/jcem-45-3-597. [DOI] [PubMed] [Google Scholar]
  8. Foti A. G., Herschman H., Cooper J. F. Isozymes of acid phosphatase in normal and cancerous human prostatic tissue. Cancer Res. 1977 Nov;37(11):4120–4124. [PubMed] [Google Scholar]
  9. Heber D., Swerdloff R. S. Male contraception; synergism of gonadotropin-releasing hormone analog and testosterone in suppressing gonadotropin. Science. 1980 Aug 22;209(4459):936–938. doi: 10.1126/science.6773142. [DOI] [PubMed] [Google Scholar]
  10. Hsueh A. J., Erickson G. F. Extra-pituitary inhibition of testicular function by luteinising hormone releasing hormone. Nature. 1979 Sep 6;281(5726):66–67. doi: 10.1038/281066a0. [DOI] [PubMed] [Google Scholar]
  11. Jaramillo Jaramillo C., Pérez-Infante V., López Maciá A., Salgado A. C., Coy D. H., Schally A. V. Serum LH, FSH and testosterone response to the administration of a new LH-RH analog, D-Trp6-LH-RH, in normal men. Int J Fertil. 1977;22(2):77–84. [PMC free article] [PubMed] [Google Scholar]
  12. Laron Z., Kauli R., Zeev Z. B., Comaru-Schally A. M., Schally A. V. D-TRP5-analogue of luteinising hormone releasing hormone in combination with cyproterone acetate to treat precocious puberty. Lancet. 1981 Oct 31;2(8253):955–956. doi: 10.1016/s0140-6736(81)91155-7. [DOI] [PubMed] [Google Scholar]
  13. Linde R., Doelle G. C., Alexander N., Kirchner F., Vale W., Rivier J., Rabin D. Reversible inhibition of testicular steroidogenesis and spermatogenesis by a potent gonadotropin-releasing hormone agonist in normal men: an approach toward the development of a male contraceptive. N Engl J Med. 1981 Sep 17;305(12):663–667. doi: 10.1056/NEJM198109173051203. [DOI] [PubMed] [Google Scholar]
  14. Mikhail G., Wu C. H., Ferin M., Vande Wiele R. L. Radioimmunoassay of plasma estrone and estradiol. Steroids. 1970 Mar;15(3):333–352. doi: 10.1016/s0039-128x(70)80053-8. [DOI] [PubMed] [Google Scholar]
  15. Redding T. W., Schally A. V. Inhibition of prostate tumor growth in two rat models by chronic administration of D-Trp6 analogue of luteinizing hormone-releasing hormone. Proc Natl Acad Sci U S A. 1981 Oct;78(10):6509–6512. doi: 10.1073/pnas.78.10.6509. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Sandow J., Von Rechenberg W., Jerzabek G., Stoll W. Pituitary gonadotropin inhibition by a highly active analog of luteinizing hormone-releasing hormone. Fertil Steril. 1978 Aug;30(2):205–209. doi: 10.1016/s0015-0282(16)43461-8. [DOI] [PubMed] [Google Scholar]
  17. Schally A. V., Arimura A., Coy D. H. Recent approaches to fertility control based on derivative of LH-RH. Vitam Horm. 1980;38:257–323. doi: 10.1016/s0083-6729(08)60487-2. [DOI] [PubMed] [Google Scholar]
  18. Schally A. V., Coy D. H., Arimura A. LH-RH agonists and antagonists. Int J Gynaecol Obstet. 1980;18(5):318–324. doi: 10.1002/j.1879-3479.1980.tb00507.x. [DOI] [PubMed] [Google Scholar]
  19. Smith R., Donald R. A., Espiner E. A., Stronach S. The effects of prolonged administration of D-Ser (TBU)6-LH-RH-EA10 (HOE 766) in subjects with hypogonadotrophic hypogonadism. Clin Endocrinol (Oxf) 1979 Nov;11(5):553–559. doi: 10.1111/j.1365-2265.1979.tb03108.x. [DOI] [PubMed] [Google Scholar]
  20. Sundaram K., Cao Y. Q., Wang N. G., Bardin C. W., Rivier J., Vale W. Inhibition of the action of sex steroids by gonadotropin-releasing hormone (GnRH) agonists: a new biological effect. Life Sci. 1981 Jan 5;28(1):83–88. doi: 10.1016/0024-3205(81)90369-6. [DOI] [PubMed] [Google Scholar]
  21. Séguin C., Cusan L., Bélanger A., Kelly P. A., Labrie F., Raynaud J. P. Additive inhibitory effects of treatment with an LHRH agonist and an antiandrogen on androgen-dependent tissues in the rat. Mol Cell Endocrinol. 1981 Jan;21(1):37–41. doi: 10.1016/0303-7207(81)90028-9. [DOI] [PubMed] [Google Scholar]
  22. Tolis G., Mehta A., Comaru-Schally A. M., Schally A. V. Suppression of androgen production by D-tryptophan-6-luteinizing hormone-releasing hormone in man. J Clin Invest. 1981 Sep;68(3):819–822. doi: 10.1172/JCI110320. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Wass J. A., Besser G. M., Gomez-Pan A., Scanlon M. F., Hall R., Kastin A. J., Coy D. H., Schally A. V. Comparison of long-acting analogues of luteinizing hormone releasing hormone in man. Clin Endocrinol (Oxf) 1979 Apr;10(4):419–430. doi: 10.1111/j.1365-2265.1979.tb02098.x. [DOI] [PubMed] [Google Scholar]
  24. Wiegelmann W., Solbach H. G., Kley H. K., Nieschlag E., Rudorff K. H., Krüskemper H. L. Effect of a new LH-RH analogue (D-Ser(TBU)6-EA10-LH-RH) on gonadotrophin and gonadal steroid secretion in men. Horm Res. 1976;7(1):1–10. doi: 10.1159/000178702. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES